stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Gross margin
Alnylam Pharmaceuticals, Inc.'s gross margin over the twelve months to 30 September 2026 was 77.3%, down 4.4 percentage points from fiscal 2025 (81.6%). Over the past ten years it has ranged from 81.6% (fiscal 2025) to 100.0% (fiscal 2017) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 81.6% | (3.98) |
| FY2024 | 85.6% | 2.60 |
| FY2023 | 83.0% | (0.71) |
| FY2022 | 83.7% | 0.33 |
| FY2021 | 83.4% | (0.76) |
| FY2020 | 84.2% | (4.44) |
| FY2019 | 88.6% | (8.99) |
| FY2018 | 97.6% | (2.41) |
| FY2017 | 100.0% | 0.00 |
| FY2016 | 100.0% | 0.00 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 75.2% | (1.69) |
| Jun 2026 | 76.9% | (5.03) |
| Mar 2026 | 81.9% | 6.31 |
| Dec 2025 | 75.6% | (8.38) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| EXEL Exelixis, Inc. compare | 96.3% |
| BBIO BridgeBio Pharma, Inc. compare | 94.3% |
| INCY Incyte Corporation compare | 92.7% |
| ASND Ascendis Pharma A/S compare | 91.3% |
| JAZZ Jazz Pharmaceuticals PLC compare | 89.1% |
| INSM Insmed, Inc. compare | 84.4% |
| ROIV Roivant Sciences Ltd. compare | 81.2% |
| ALNY Alnylam Pharmaceuticals, Inc. | 77.3% |
| BNTX BioNTech SE Sponsored ADR compare | 74.6% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement